Teva Pharm Stock Price, News & Analysis

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) plans to release its third quarter 2022 financial results on November 3, 2022, at 7:00 a.m. ET. A conference call and live webcast will follow at 8:00 a.m. ET. Investors must register in advance to participate. The event will be available for replay on Teva's website within 24 hours post-call. Teva is recognized for its extensive portfolio of over 3,500 products, impacting 200 million patients daily, and has a strong commitment to innovation in specialty and biopharmaceuticals.

Teva Pharmaceuticals has launched a significant 3-year longitudinal study to explore the effects of tardive dyskinesia and treatment with AUSTEDO (deutetrabenazine). This Phase 4 multicenter study aims to gather real-time data on the impact of TD, impacting one in four patients on certain mental health medications. The study will collect comprehensive information on the progression of TD, capturing both patient and clinician-reported outcomes. Approximately 600 patients will be enrolled across 45 centers in the U.S.

Teva Pharmaceuticals has reached a settlement with the Attorney General of Georgia, agreeing to pay $3.346 million to resolve price-fixing claims. This settlement will lead to the dismissal of all claims against Teva and its affiliates once paid. Teva has previously settled similar litigation with Mississippi and Louisiana. The company continues to deny the allegations but remains committed to compliance and robust antitrust training. Teva aims to focus on delivering quality medicines while addressing legacy litigation matters, including discussions with other states regarding settlements.

Teva Pharmaceuticals has launched the Honestly HD website to assist the Huntington's Disease (HD) community in understanding chorea symptoms and communicating with healthcare providers. The site offers resources for managing HD chorea, which affects 90% of those with HD, potentially impacting daily life. Alongside the website, a Twitter channel and Facebook community have been introduced to foster support. Teva emphasizes its commitment to helping patients navigate the challenges posed by this degenerative disease.

Teva Pharmaceutical Industries has presented two studies at the Migraine Trust International Symposium (MTIS) in London, showcasing the efficacy of AJOVY (fremanezumab) for treating migraine in patients with co-morbid depression and anxiety. Results showed over 50% reduction in monthly migraine attacks in patients taking AJOVY compared to placebo. The studies highlight the importance of addressing psychiatric comorbidities in migraine treatment. Teva aims to provide personalized treatment options, with ongoing research including the UNITE study assessing AJOVY's effectiveness in managing chronic migraine with major depressive disorder.

Teva Pharmaceuticals announced promising results from the CONNECT1 study, comparing the ProAir Digihaler to standard albuterol inhalers for asthma management. Patients using the Digihaler saw an 85.3% increase in improving asthma control after three months. The study, involving 333 participants, highlighted that those with the Digihaler had better adherence discussions with physicians and experienced fewer SABA inhalations. Additionally, 61% of Digihaler users achieved well-controlled asthma compared to 55% in the standard care group. The findings underscore the potential of digital tools in asthma management.

Pyramid Biosciences has expanded its leadership team by appointing Biren Amin as Chief Financial and Strategy Officer. Amin, previously CFO at Immuneering Corporation (NASDAQ: IMRX), brings over two decades of experience in oncology and biotechnology. The company is focused on developing precision therapies for cancer, particularly with its lead program PBI-200, a TRK inhibitor for NTRK fusion-driven cancers. The CEO expressed confidence in Amin's expertise to guide corporate strategy and advance the product pipeline during a period of significant growth for the company.

Teva Pharmaceutical Industries announced findings from the CONNECT clinical program regarding the ProAir Digihaler System, designed to enhance asthma control. The CONNECT1 trial assessed 333 asthma patients over 12 weeks and compared the Digihaler's effects on asthma management against standard care. Initial results will be presented at the European Respiratory Society Congress on September 6, 2022, focusing on asthma control improvements and enhancing patient-physician interactions. The ProAir Digihaler incorporates an electronic module to track inhaler use and support informed treatment decisions.

Teva Pharmaceuticals has received Marketing Authorization from the European Commission for Ranivisio (ranibizumab), a biosimilar to Lucentis, targeting age-related macular degeneration (AMD) and four other ophthalmology indications. AMD currently affects approximately 67 million individuals in Europe and is predicted to impact up to 77 million by 2050. Teva aims to commercialize this product across Europe through a partnership with Bioeq AG, following its UK launch in July 2022 under the name ONGAVIA®.